

Serial No. 10/606,422
 Reply and Amendment dated June 20, 2006
 Responding to Office Action dated April 20, 2006


Docket No. ORT-1222 USA DIV

Listing of Claims

Claims 1-27 (Canceled)

28. (Currently Amended) A method of inhibiting platelet aggregation in a subject in need thereof comprising the steps of:

a) selecting a thrombin receptor antagonist compound of Formula II: A method of Claim 27 wherein said compound is selected from a compound of Formula II:



wherein:

Y	A ₁	A ₂	X
5-(o-Cl-cinnamamido)triazol-3-yl	Cha	Arg	CO
5-(Thien-2-ylacrylamido) triazol-3-yl	Cha	Arg	CO
5-(Cinnamamido)triazol-3-yl	Cha	Arg	CO
5-(α-Me-cinnamamido) triazol-3-yl	Cha	Arg	CO
5-(α-Ph-cinnamamido) triazol-3-yl	Cha	Arg	CO
6-Cinnamamidopyridin-3-yl	Cha	Arg	CO
5-Cl, 3-Me-benzothiophen-2-yl	Cha	Arg	SO ₂

Serial No. 10/606,422
 Reply and Amendment dated June 20, 2006
 Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV

<u>Y</u>	<u>A₁</u>	<u>A₂</u>	<u>X</u>
5-(p-F-cinnamamido) triazol-3-yl	Cha	Arg	CO
Benzothiophen-2-yl	Cha	Arg	CO
1-naphthyl	Cha	Arg	SO ₂
2-naphthyl	Cha	Arg	SO ₂

or

any pharmaceutically acceptable salt thereof; and

b) administering said compound to the subject.

29. (Currently Amended) A method of Claim 278 wherein said compound is selected from the group consisting essentially of:

[5-cinnamamidotriazol-3-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(6-Cinnamamidopyridin-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide; and

(5-Chloro-3-methyl-benzothiophen-2-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide.

30. (Currently Amended) The method of Claim 278, wherein ~~the therapeutically effective amount of~~ the compound is administered to the subject in an amount from about 0.1 to about 300 mg/kg/day.

31. (Currently Amended) The method of Claim 30, wherein the ~~therapeutically effective~~ amount of the compound is about 1 to about 50 mg/kg/day.


32. (Cancelled).

Serial No. 10/606,422
 Reply and Amendment dated June 20, 2006
 Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV

33. (Currently Amended) A method of inducing platelet aggregation in a subject in need thereof comprising the steps of:

a) selecting a thrombin receptor antagonist compound of Formula III: A method of Claim 32 wherein said compound is selected from a compound of Formula II:



wherein:

Y	A ₁	A ₂	A ₃
5-H ₂ N-1,2,4-triazol-3-yl	Cha	Arg	Phe
5-Bromopyridin-3-yl	Cha	Arg	Phe
2-Chromonyl	Cha	Arg	Phe
5-(α-Me-cinnamamido)triazol-3-yl	Cha	Arg	Phe
5-Naphthylacrylamidotriazol-3-yl	Cha	Arg	Phe
Quinoxalin-2-yl	Cha	Arg	Phe
5-(o-Cl-cinnamamido)triazol-3-yl	Cha	Arg	Phe
6-Aminopyridin-3-yl	Cha	Arg	Phe
5-H ₂ N-1,2,4-triazol-3-yl	Cha	Arg	Phe-Arg
Thiadiazol-4-yl	Cha	Arg	Phe

Serial No. 10/606,422
 Reply and Amendment dated June 20, 2006
 Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV

Y	A ₁	A ₂	A ₃
5-(2,3-diMeO-cinnamamido)triazol-3-yl	Cha	Arg	Phe
5-(α -F-cinnamamido)triazol-3-yl	Cha	Arg	Phe
5-(<i>m</i> -NO ₂ -cinnamamido)triazol-3-yl	Cha	Arg	Phe
5-(<i>o</i> -NO ₂ -cinnamamido)triazol-3-yl	Cha	Arg	Phe
Pyridin-3-yl	Cha	Arg	Phe
5-(<i>m</i> -Cl-cinnamamido)triazol-3-yl	Cha	Arg	Phe
5-H ₂ N-1,2,4-triazol-3-yl	Phe	Arg	Phe
5-H ₂ N-1,2,4-triazol-3-yl	Cha	Lys	Phe
5-H ₂ N-1,2,4-triazol-3-yl	Cha	Arg	Cha
5-H ₂ N-1,2,4-triazol-3-yl	Cha	Arg	Phgly
5-(thiophen-2-ylacrylamido)triazol-3-yl	Cha	Arg	Phe
3-H ₂ N-pyrazin-2-yl	Cha	Arg	Phe
trans 2-(3-pyridyl)ethylenyl	Cha	Arg	Phe
5-(<i>p</i> -MeO-cinnamamido)triazol-3-yl	Cha	Arg	Phe
5-(<i>p</i> -CN-cinnamamido)triazol-3-yl	Cha	Arg	Phe
5-(<i>p</i> -F-cinnamamido)triazol-3-yl	Cha	Arg	Phe

Serial No. 10/606,422
 Rcply and Amendment dated June 20, 2006
 Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV

<u>Y</u>	<u>A₁</u>	<u>A₂</u>	<u>A₃</u>
2-H ₂ N-pyridin-3-yl	Cha	Arg	Phe
5-H ₂ N-1,2,4-triazol-3-yl	Cha	Arg	Tyr
5-H ₂ N-1,2,4-triazol-3-yl	Cha	Arg	2-Thala
Pyridin-2-yl	Cha	Arg	Phe
5-(p-Phenyl-cinnamamido)triazol-3-yl	Cha	Arg	Phe
N-(p-F-phenylalanyl)-piperidin-3-yl	Cha	Arg	Phe
5-(Cinnamamido)triazol-3-yl	Cha	Arg	Phe
5-(α-phenyl-cinnamamido)triazol-3-yl	Cha	Arg	Phe
3-aminophenyl	Cha	Arg	Phe
1-biphenyl	Cha	Arg	Phe
2-biphenylenyl	Cha	Arg	Phe
benzimidazol-5-yl	Cha	Arg	Phe

and any pharmaceutically acceptable salt thereof; and

b) administering said compound to the subject.

34. (Currently Amended) A method of Claim 323 wherein said compound is selected from the group consisting essentially of:

(5-Bromopyridin-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

2-Chromonylcarbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

Serial No. 10/606,422
Reply and Amendment dated June 20, 2006
Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV

(5-Aminotriazol-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

[5-(α -Methyl)cinnamamidotriazol-3-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

{5-[3-(1-Naphthyl)acrylamido]triazol-3-yl}carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

[Quinoxalin-2-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

[5-(*o*-Chlorocinnamamido)triazol-3-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(6-Aminopyridin-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(5-Aminotriazol-3-yl)carbonyl-phenylalanyl-arginyl-phenylalanyl-arginineamide;

(5-Aminotriazol-3-yl)carbonyl-cyclohexylalanyl-lysiny-phenylalanineamide; and

{5-[3-(2-Thienyl)acrylamido]triazol-3-yl}carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide.

35. (Currently Amended) The method of Claim 32~~3~~, wherein ~~the therapeutically effective amount of~~ the compound is administered to the subject in an amount from about 0.1 to about 300 mg/kg/day.


36. (Currently Amended) The method of Claim 35, wherein the ~~therapeutically effective~~ amount of the compound is about 1 to about 50 mg/kg/day.

37. (Cancelled).

38. (Currently Amended) ~~A method of Claim 37 wherein said compound is selected from a compound of Formula A~~ A method of treating a platelet-mediated thrombotic disorder selected from the group consisting of myocardial infarction, stroke, angina, and ischemic attacks in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula II:

Serial No. 10/606,422
 Reply and Amendment dated June 20, 2006
 Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV



wherein:

Y	A ₁	A ₂	X
5-(o-Cl-cinnamamido)triazol-3-yl	Cha	Arg	CO
5-(Thien-2-ylacrylamido) triazol-3-yl	Cha	Arg	CO
5-(Cinnamamido)triazol-3-yl	Cha	Arg	CO
5-(α-Me-cinnamamido) triazol-3-yl	Cha	Arg	CO
5-(α-Ph-cinnamamido) triazol-3-yl	Cha	Arg	CO
6-Cinnamamidopyridin-3-yl	Cha	Arg	CO
5-Cl, 3-Me-benzothiophen-2-yl	Cha	Arg	SO ₂
5-(p-F-cinnamamido) triazol-3-yl	Cha	Arg	CO
Benzothiophen-2-yl	Cha	Arg	CO
1-naphthyl	Cha	Arg	SO ₂
2-naphthyl	Cha	Arg	SO ₂

or any pharmaceutically acceptable salt thereof.

Serial No. 10/606,422
 Reply and Amendment dated June 20, 2006
 Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV

39. (Currently Amended) A method of Claim 378 wherein said compound is selected from the group consisting essentially of:

[5-cinnamamidotriazol-3-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(6-Cinnamamidopyridin-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide; and


(5-Chloro-3-methyl-benzothiophen-2-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide.

40. (Currently Amended) The method of Claim 378, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

41. (Previously Presented) The method of Claim 40, wherein the therapeutically effective amount of the compound is about 1 to about 50 mg/kg/day.

42. (Cancelled).

43. (Currently Amended) ~~A method of Claim 42 wherein said compound is selected from a compound of Formula A~~ A method of treating restenosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula II:



wherein:

Y	A ₁	A ₂	X
5-(o-Cl-cinnamamido)triazol-3-yl	Cha	Arg	CO

Serial No. 10/606,422
 Reply and Amendment dated June 20, 2006
 Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV

Y	A ₁	A ₂	X
5-(Thien-2-ylacrylamido) triazol-3-yl	Cha	Arg	CO
5-(Cinnamamido)triazol-3-yl	Cha	Arg	CO
5-(α -Me-cinnamamido) triazol-3-yl	Cha	Arg	CO
5-(α -Ph-cinnamamido) triazol-3-yl	Cha	Arg	CO
6-Cinnamamidopyridin-3-yl	Cha	Arg	CO
5-Cl, 3-Me-benzothiophen-2-yl	Cha	Arg	SO ₂
5-(p-F-cinnamamido) triazol-3-yl	Cha	Arg	CO
Benzothiophen-2-yl	Cha	Arg	CO
1-naphthyl	Cha	Arg	SO ₂
2-naphthyl	Cha	Arg	SO ₂

or any pharmaceutically acceptable salt thereof.

44. (Currently Amended) A method of Claim 423 wherein said compound is selected from the group consisting essentially of:

[5-cinnamamidotriazol-3-yl]carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide;

(6-Cinnamamidopyridin-3-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide; and

Serial No. 10/606,422
Reply and Amendment dated June 20, 2006
Responding to Office Action dated April 20, 2006

Docket No. ORT-1222 USA DIV

(5-Chloro-3-methyl-benzothiophen-2-yl)carbonyl-cyclohexylalanyl-arginyl-phenylalanineamide.

45. (Currently Amended) The method of Claim 423, wherein the therapeutically effective amount of the compound is about 0.1 to about 300 mg/kg/day.

46. (Previously Presented) The method of Claim 45, wherein the therapeutically effective amount of the compound is about 1 to about 50 mg/kg/day.